Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Malignant Lymphoma

  Free Subscription


1 Am J Hematol
3 Blood
1 BMC Cancer
6 Br J Haematol
1 Haematologica
1 Int J Cancer
3 J Am Acad Dermatol
1 J Virol
4 Leuk Lymphoma
1 Leukemia

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Hematol

  1. KARMALI R, Switchenko JM, Goyal S, Shanmugasundaram K, et al
    Multi-Center Analysis of Practice Patterns and Outcomes of Younger and Older Patients with Mantle Cell Lymphoma in the Rituximab Era.
    Am J Hematol. 2021 Jul 29. doi: 10.1002/ajh.26306.
    PubMed         Abstract available


  2. XU W, Berning P, Lenz G
    Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma.
    Blood. 2021 Jul 28. pii: 476467. doi: 10.1182/blood.2020006784.
    PubMed         Abstract available

  3. DUNS G, Vigano E, Ennishi D, Sarkozy C, et al
    Characterization of DLBCL with a PMBL gene expression signature.
    Blood. 2021;138:136-148.
    PubMed         Abstract available

  4. SHAH NN, Ahn KW, Litovich C, He Y, et al
    Is autologous transplant in relapsed DLBCL patients achieving only a PET+ PR appropriate in the CAR T-cell era?
    Blood. 2021;137:1416-1423.
    PubMed         Abstract available

    BMC Cancer

  5. BOOTH SW, Eyre TA, Whittaker J, Campo L, et al
    A Phase 2a cohort expansion study to assess the safety, tolerability, and preliminary efficacy of CXD101 in patients with advanced solid-organ cancer expressing HR23B or lymphoma.
    BMC Cancer. 2021;21:851.
    PubMed         Abstract available

    Br J Haematol

  6. GAILLLARD B, Cornillet-Lefebvre P, Le QH, Maloum K, et al
    Clinical and biological features of B-cell neoplasms with CDK6 translocations: an association with a subgroup of splenic marginal zone lymphomas displaying frequent CD5 expression, prolymphocytic cells, and TP53 abnormalities.
    Br J Haematol. 2021;193:72-82.
    PubMed         Abstract available

  7. OLUWOLE OO, Bouabdallah K, Munoz J, De Guibert S, et al
    Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma.
    Br J Haematol. 2021 Jul 22. doi: 10.1111/bjh.17527.
    PubMed         Abstract available

  8. ALCOCEBA M, Garcia-Alvarez M, Chillon MC, Jimenez C, et al
    Liquid biopsy: a non-invasive approach for Hodgkin lymphoma genotyping.
    Br J Haematol. 2021 Jul 27. doi: 10.1111/bjh.17719.
    PubMed         Abstract available

  9. RINALDI F, Marchesi F, Palombi F, Pelosi A, et al
    MiR-22, a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients.
    Br J Haematol. 2021 Jul 28. doi: 10.1111/bjh.17734.
    PubMed         Abstract available

  10. LYU R, Wang T, Wang Y, Xiong W, et al
    Undetectable minimal residual disease is an independent prognostic factor in splenic marginal zone lymphoma.
    Br J Haematol. 2021 Jul 30. doi: 10.1111/bjh.17703.
    PubMed         Abstract available

  11. DANILOV AV, Persky DO
    Incorporating acalabrutinib, a selective next-generation Bruton tyrosine kinase inhibitor, into clinical practice for the treatment of haematological malignancies.
    Br J Haematol. 2021;193:15-25.
    PubMed         Abstract available


  12. GURION R, Rozovski U, Itchaki G, Gafter-Gvili A, et al
    Humoral serologic response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies.
    Haematologica. 2021 Jul 29. doi: 10.3324/haematol.2021.279216.
    PubMed         Abstract available

    Int J Cancer

  13. GAUT D, Tang K, Sim MS, Duong T, et al
    Filgrastim associations with CAR T-cell therapy.
    Int J Cancer. 2021;148:1192-1196.
    PubMed         Abstract available

    J Am Acad Dermatol

  14. TUNG JK, Rozenbaum D, Rrapi R, Chand S, et al
    Skin biopsy in the diagnosis of intravascular lymphoma: a retrospective diagnostic accuracy study.
    J Am Acad Dermatol. 2021 Jul 24. pii: S0190-9622(21)02168.

  15. ENZAN N, Kitadate A, Kono M
    Comment on skin biopsies for diagnosing intravascular lymphoma: a retrospective study of diagnostic accuracy.
    J Am Acad Dermatol. 2021 Jul 23. pii: S0190-9622(21)02167.

  16. KARTAN S, Shalabi D, O'Donnell M, Alpdogan SO, et al
    Response to topical corticosteroid monotherapy in mycosis fungoides.
    J Am Acad Dermatol. 2021;84:615-623.
    PubMed         Abstract available

    J Virol

  17. LU J, Verma SC, Murakami M, Cai Q, et al
    Correction for Lu et al., "Latency-Associated Nuclear Antigen of Kaposi's Sarcoma-Associated Herpesvirus (KSHV) Upregulates Survivin Expression in KSHV-Associated B-Lymphoma Cells and Contributes to Their Proliferation".
    J Virol. 2021;95:e0076121.

    Leuk Lymphoma

  18. HORWITZ S, Zinzani PL, Bagot M, Kim YH, et al
    Lack of impact of type and extent of prior therapy on outcomes of mogamulizumab therapy in patients with cutaneous T cell lymphoma in the MAVORIC trial.
    Leuk Lymphoma. 2021 Jul 26:1-10. doi: 10.1080/10428194.2021.1953007.
    PubMed         Abstract available

  19. TAO Y, He X, Qin Y, Liu P, et al
    Low platelet/platelet distribution width and high platelet/lymphocyte ratio are adverse prognostic factors in patients with newly diagnosed advanced Hodgkin lymphoma.
    Leuk Lymphoma. 2021 Jul 23:1-11. doi: 10.1080/10428194.2021.1953015.
    PubMed         Abstract available

  20. TOBIN JWD, Crothers A, Ma TE, Mollee P, et al
    A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma.
    Leuk Lymphoma. 2021 Jul 29:1-9. doi: 10.1080/10428194.2021.1957866.
    PubMed         Abstract available

  21. PLATTEL WJ, Bergamasco A, Trinchese F, Gavini F, et al
    Effectiveness of brentuximab vedotin monotherapy in relapsed or refractory Hodgkin lymphoma: a systematic review and meta-analysis.
    Leuk Lymphoma. 2021 Jul 29:1-13. doi: 10.1080/10428194.2021.1957865.
    PubMed         Abstract available


  22. ROSSI A, Orecchioni S, Falvo P, Tabanelli V, et al
    Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma.
    Leukemia. 2021 Jul 24. pii: 10.1038/s41375-021-01347.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.